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Amyotrophic lateral sclerosis (ALS) is a severe disease causing motor neuron death, but a
complete cure has not been developed and related genes have not been defined in more than
80% of cases. Here we compared whole genome sequencing results from a male ALS patient
and his healthy parents to identify relevant variants, and chose one variant in the X-linked
ATP7A gene, M1311V, as a strong disease-linked candidate after profound examination.
Although this variant is not rare in the Ashkenazi Jewish population according to results in
the genome aggregation database (gnomAD), CRISPR-mediated gene correction of this
mutation in patient-derived and re-differentiated motor neurons drastically rescued neuronal
activities and functions. These results suggest that the ATP7A M1311V mutation has a
potential responsibility for ALS in this patient and might be a potential therapeutic target,
revealed here by a personalized medicine strategy.
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DNA sequencing technologies have evolved in highthroughput manners to generate tremendous volume ofdata inexpensively, since the development of Sanger
sequencing in 19771. Now, personalized whole genome infor-
mation can easily be obtained via next-generation sequencing
(NGS)2,3. Such advances suggest that individualized treatment
might be possible in genetic disorders, such as neurodegenerative
diseases4. In previous studies, rare disorder-linked mutations
were discovered using family based whole genome or exome
sequencing for autism, Alzheimer’s disease, ALS, and Parkinson’s
disease5–10. In biological research, pathogenicity in individual
patient can be determined via in vitro disease modeling using
induced pluripotent stem (iPS) cells derived from the patient,
which reflect full genetic information of the patient11–15. Fur-
thermore, programmable nucleases, including CRISPR-Cas
(clustered, regularly interspaced short palindromic repeats, and
CRISPR-associated) nucleases, enable single nucleotide substitu-
tions very accurately at desired target sites16–19. Through targeted
gene editing of known disease variant in patient-derived iPS cells
via CRISPR-Cas nucleases, pathologic metabolisms, such as sig-
naling pathway, transcripts change, and functional rescue of a
gene have been investigated for Huntington’s disease, cardiac
disease, and ALS20–22.
Amyotrophic lateral sclerosis (ALS; or Lou Gehrig’s disease),
an adult onset neurodegenerative disease, is characterized by the
loss of motor neurons (MNs), muscle weakness, and death from
respiratory failure within 3 years from the onset of symptoms for
half of all patients23,24. Most cases are sporadic; only about 10%
of individuals with ALS have a familial history. Since mutations in
the superoxide dismutase 1 (SOD1) gene were first revealed to
cause ALS disease25, mutations in over 20 other genes have been
linked to ALS. Until now, variants on SOD1 gene have deeply
been studied from patient-derived iPS cells using CRISPR-Cas9
nucleases. Comparison studies between MNs differentiated from
ALS patient-derived iPS cells and MNs from SOD1 gene corrected
cell lines revealed that functional changes by SOD1 mutations
induce neurodegeneration and aberrant gene expression, resulting
in vulnerable oxidative stress, altered protein response pathway,
ER stress, and mitochondrial defect26–28. In more than 80% of
ALS cases, however, the responsible genes for ALS still remain
unclear29–31. Therefore, there is an important need to elucidate
additional ALS-relevant genes from ALS patients.
Because of rapid improvements in DNA sequencing, iPS cells,
and gene editing technologies, investigations of the relationship
between genotype and phenotype in each patient can be realized.
In this study, we combined the whole genome sequencing (WGS)
and CRISPR-Cas9 mediated gene editing technologies to identify
disease linked mutations in an ALS patient, as well as to verify the
disease relevance of the mutation in patient-derived iPS cells,
suggesting the strategy of personalized medicine.
Results
Trio-based WGS identifies responsible variants in a patient. In
the case of a patient of Jewish origin who was diagnosed with bi-
brachial type sporadic ALS disease in his sixties, we tried to
identify susceptibility genes for personalized ALS treatment.
Because the patient had no mutations in the previously reported
genes related to ALS, we carried out a trio-based WGS study of
this patient and his healthy parents to identify genetic mutations
causing ALS. The whole workflow of WGS data analysis is
summarized in Fig. 1, and detailed pipelines are described in
Supplementary Fig. 1. The trio WGS data were analyzed based on
pedigree information in X-linked, recessive, or de novo genetic
mode; we excluded the possibility of autosomal dominant
inheritance because the patient’s parents were healthy. We
annotated called variants in each inheritance mode, and prior-
itized according to the order of severity from Sequence Ontology
(SO) and the degree of pathogenicity from the American College
of Medical Genetics and Genomics (ACMG) guidelines32. Com-
mon variants frequently observed in panels of the normal
population were filtered out. Next, we evaluated functional
importance and prioritized following two workflows in parallel.
First, we selected variants with rare allele frequencies (<0.1%) in
the Ashkenazi Jewish population that were predicted to be
functionally high impact based on the order of severity as defined
by SO (Supplementary Table 1). Among 21 selected variants, we
prioritized 7 that were located in functional gene networks using
both direct (Supplementary Table 2) and indirect (Supplementary
Table 3) network-prioritization methods based on 126 ALS-
related genes registered in the ALS genetic database29 (Supple-
mentary Table 4). Second, we selected possible pathogenic
variants using two in silico analysis tools, Polyphen-2 and SIFT,
according to the ACMG guidelines. We evaluated the pathogenic
impact of each variant on the function and structure of the
corresponding protein and then prioritized 2 variants with higher
pathogenic scores (Supplementary Table 5). From the above two
independent criteria, we obtained 9 candidate variants that were
possibly pathogenic in ALS.
We excluded four of the nine variants because of predictions
that they were related to conditions other than neurodegenerative
disease and because they were located in non-functional domains
of the genes (Supplementary Table 6). For the remaining five
variants, we performed genotyping to determine a zygosity of
each gene variant using Sanger sequencing (Supplementary
Fig. 2). The results revealed that variants in DTX1 and NOTCH2
were false positive; i.e. each site only contained wild type
sequence rather than frameshift or missense variant that was
expected from WGS. And the variants in GFRA2 and GART were
identified to be heterozygous; i.e. one allele in each site had wild
type sequence. On the other hand, ATP7A located on the X
chromosome had a mutated variant only likewise to WGS data,
identified to be hemizygous because the patient is male33.
Throughout the prioritization process, we selected the ATP7A
variant as a strong candidate for causing the disease. The ATP7A
protein, a transmembrane P-type ATPase, has a well-
characterized role in maintaining intracellular copper (Cu)
concentrations, which are essential for regulating the activity of
Cu-dependent enzymes that function in oxidation/reduction
reactions, signaling pathways, and metabolism34–37.
In conclusion, the filtering steps described above indicate that
the M1311V mutation in the ATP7A gene may be causative in the
etiology of ALS (Fig. 1). The ATP7A gene is X-linked and we
found that the mother of the ALS patient in question was a carrier
of the M1311V mutation (Supplementary Fig. 3). Our selection is
further supported by previous studies showing that abnormal Cu
homeostasis increases the production of reactive oxygen species
(ROS), resulting in cellular damage, neurodegeneration, and
neuroinflammation35–37, and by other studies showing that
several ATP7A variants are linked with neurodegenerative
diseases such as Menkes disease, occipital horn syndrome, and
X-linked distal spinal muscular atrophy type 3, which show
similar symptoms as ALS37 (Supplementary Fig. 4).
CRISPR-mediated gene correction in patient-derived iPS cells.
The best way to prove correlation between the ATP7A M1311V
mutation and the ALS disease in the patient is to compare the
phenotype of patient-derived neurons containing the ATP7A
M1311V mutation against that of corrected neurons, because the
two cell types would have identical backgrounds except for the
ATP7A mutation (Fig. 2a). To generate ATP7A-corrected cell
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lines, we first constructed iPS cells, named ATP7A-M1311V,
from the patient’s fibroblasts. Then, we transfected CRISPR-Cas9
nuclease into the iPS cells along with single-stranded oligodeox-
ynucleotides (ssODNs) as the donor DNA for gene correction
(Fig. 2b and Supplementary Fig. 5). We initially measured a
correction rate of 0.4% from the bulk iPS cells via targeted deep
sequencing38, so we repetitively divided them into small popu-
lations of cells. After five repeated clump passages, we ultimately
obtained two completely corrected iPS cell lines (Fig. 2c), named
ATP7A-Cor1 and ATP7A-Cor2.
To investigate the side effects by CRISPR-Cas9, we examined
the mutations at predicted potential off-target sites that had 1–3-
nt mismatches or 1-nt DNA or RNA bulges using Cas-OFFinder
software39 in the two corrected cell lines. We performed targeted
deep sequencing for 14 sites but detected no significant off-target
effects (Supplementary Tables 7–9). In addition, we checked
whether the gross organization of the chromosomal DNA of the
ATP7A-Cor lines was damaged during the gene editing process
using karyotyping. Both ATP7A-Cor lines showed normal
karyotype morphologies, as did ATP7A-M1311V (Fig. 2d).
Sanger sequencing was performed to confirm the gene corrected
sequence in differentiated cell type, neural progenitor cells
(NPCs) and MNs (Fig. 2e), indicating that CRISPR-mediated
gene correction gave no substantial effects to the iPS cells.
Gene correction of the ATP7A M1311V leads to improvement.
To compare the pathologic phenotype and neuronal function of
the ATP7A-M1311V and ATP7A-Cor lines, we next differ-
entiated the ATP7A-M1311V, ATP7A-Cor1, and ATP7A-Cor2
lines to neural progenitor cells (NPCs) and measured lysyl
oxidase (LOX) activities and ROS levels in each case. LOX is a
Cu-dependent enzyme that is activated by Cu transported by
ATP7A40. Compared to the ATP7A-M1311V-NPC line, ATP7A-
Cor1-NPC and ATP7A-Cor2-NPC showed increased LOX
activities and produced lower ROS levels that were comparable to
those from control NPCs from a healthy donor (Supplementary
Fig. 6). These results support the premise that ATP7A gene
correction may improve ATP7A function and ALS pathology
in NPCs.
Given this evidence, we further differentiated one of the
corrected NPC lines, ATP7A-Cor1-NPC, as well as ATP7A-
M1311V-NPC and the control NPCs, to MNs (Fig. 3a), as
follows. NPCs were initially purified using a cell surface marker,
polysialic acid-neural cell adhesion molecule (PSA-NCAM), to
eliminate non-neuronal cells from cell population of neural
rosettes41. Most PSA-NCAM positive NPCs consistently showed
to retain high level of neural cell markers, Nestin and Tuj1 in each
cell line (Fig. 3b, c). NPCs were differentiated in motor neuron
differentiation medium for 3 weeks and ultimately exhibited a
motor neuron positive marker, Isl1/2 (Fig. 3d, e). To determine
whether gene correction of ATP7A-M1311V affect neurite
complexity, we measured the expression level of a neuronal
marker, microtubule associated protein 2 (MAP2), in each line by
immunostaining and also visualized nuclei by 4′, 6-diamidino-2-
phenylindole (DAPI) staining. The quantitative differentiation
ratios calculated by comparison of the DAPI and MAP2 positive
areas indicated that ATP7A-M1311V-MN showed reduced
MAP2 level compared with ATP7A-Cor1-MN, which showed
similar efficacy as the control line (Fig. 3f, g), implying declined
regulating of neuritic maintenance and microtubule networks in
dendritic morphologenesis42–44 in the ATP7A-M1311V line and
recovery from this effect in the ATP7A-Cor1 line.
For each set of differentiated MNs, we measured the
concentration of released lactate dehydrogenase (LDH), a
measure of cell damage. LDH release was higher in ATP7A-
Fig. 1 Filtering strategy to identify pathogenic mutation. Trio whole genome sequencing was performed for the patient and his healthy parents to
annotate inherited and de novo mutations. Candidate variants were prioritized according to measures of functional importance including allele frequency,
high impact consequences, or in silico analysis. Variants were further prioritized using network-based prioritization or pathogenity scores. Nine variants
were determined to be high priority; this list was narrowed down by review of related diseases, predicted genomic function, and selection of candidates
with zygosity analysis. The final candidate mutation, ATP7A M1311V, was selected after a review of literature for neurodegenerative disease.
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M1311V-MN than in the control MNs, whereas release was
significantly decreased in ATP7A-Cor1-MN, comparable to the
level in the control MNs (Fig. 3h). We next measured the cell
viability and ROS levels after treatment with glutamate, which
acts as an excitatory neurotransmitter to generate action
potentials. Although glutamate plays an essential role in the
nervous system, it can also exert a neurotoxic effect, causing free
radical production, mitochondrial dysfunction, and protein
aggregation, especially in ALS-derived MNs. Cell viability
measurements showed that only 80% of ATP7A-M1311V-MN
cells survived under glutamate treatment compared to the
untreated condition, whereas most ATP7A-Cor1-MN cells
survived, similar to the control MNs, indicating rescue of the
glutamate vulnerability in ATP7A-Cor1-MN (Supplementary
Fig. 7). The ROS products significantly accumulated in ATP7A-
M1311V-MN cells under basal conditions (Fig. 3i) and when they
were treated with glutamate (Supplementary Fig. 7), whereas the
ROS level was reduced in ATP7A-Cor1-MN cells, similar to that
in the control MNs, also supporting the concept of cell function
recovery in ATP7A-Cor1-MN. To further confirm whether
mitochondria-related function was rescued in the corrected MN
lines, we measured mitochondrial membrane potentials linked to
the ROS generation using tetramethylrhodamine ethyl ester
(TMRE) assay. In line with above results of ROS, ATP7A-
M1311V-MN cells showed impaired mitochondrial membrane
potentials, whereas the TMRE level was recovered in ATP7A-
Cor1-MN cells similar to the control MNs (Fig. 3j). Taken
together, we confirmed the differences in cell viability, cellular
function and neurite complexity between ALS patient-derived
cells and ATP7A gene-corrected cells.
Improvement of neuronal activity in gene-corrected MNs. To
further compare neuronal properties, 8 weeks after MN differ-
entiation (Fig. 4a), we performed electrophysiological analyses for
each single neuron cell and four types of action potential (repe-
titive, adaptive, single, and no firing) were defined and classified
(Fig. 4b). Compared to the control MN population, in which
most cells showed firing action potentials, half of the ATP7A-
M1311V-MN cells showed non-firing action potentials. However,
to our surprise, most ATP7A-Cor1-MN cells showed firing action
potentials and the relative proportions of the firing patterns were
very similar to those of the control MNs (Fig. 4c). We found that
ATP7A-M1311V-MN cells showed the loss of voltage gated
sodium current and had smaller voltage gated potassium currents
compared to the ATP7A-Cor1-MN cells and the control MNs
(Fig. 4d, e and Supplementary Fig. 8), which explains why half of
the ATP7A-M1311V-MN cells showed non-firing action poten-
tials. These results strongly suggest the recovery of neuronal
activity in ATP7A-Cor1-MN compared to ATP7A-M1311V-MN
cells.
One potential concern about our results is that the pluripo-
tency and differentiation of iPS cells might have affected the
function of the resulting MNs. To address this issue, we
constructed induced neural stem cells (iNSCs) from the patient’s
fibroblasts (ATP7A-M1311V-iNSC) via direct conversion (Sup-
plementary Fig. 9) and compared them with control iNSCs from
a healthy donor45. We found that the ATP7A-M1311V-iNSC
population showed no difference in the proliferation rate
compared to the control iNSCs, but showed lower cell viability,
lower LOX activity, and elevated ROS under basal cell conditions,
similar to the results from the experiments with iPS cells
Fig. 2 CRISPR-mediated gene correction of the ATP7A M1311V mutation and construction of patient-derived isogenic iPS cell lines. a Overview of our
personalized medicine approach. b Strategy for correction of the ATP7A M1311V mutation in patient-derived iPS cells using CRISPR-Cas9. The ATP7A
point mutation (A to G) is shown in red. The 20-nucleotide single guide RNA (sgRNA) target sequence and the protospacer adjacent motif (PAM) are
shown in blue and yellow, respectively. The single-stranded oligodeoxynucleotides (ssODNs), which has 50-bp homology arms, was designed to change
the disease-causing mutation to the normal sequence and disrupt the PAM sequence to prevent further Cas9-mediated cleavage after the correction.
c Efficiency of homology-directed repair (HDR) for generating the gene-corrected isogenic iPS cell line. d Karyotype analysis of parental (ATP7A-M1311V)
and gene-corrected (ATP7A-Cor1 and ATP7A-Cor2) iPS cell lines. e Sanger sequencing to confirm the mutant ATP7A M1311V and normal sequence in iPS
cells, NPCs, and MNs.
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described above (Supplementary Fig. 10), supporting our
conclusion that the ATP7A M1311V mutation has a potential
responsibility for ALS.
Discussion
In this study, we revealed that the X-linked ATP7A M1311V
mutation has a potential responsibility for ALS in one male ALS
patient by comparing WGS results with his healthy parents.
Considering various factors including genetic mode, mutation
type, allele frequency, and published literature, it is acceptable
that ATP7A M1311V has high functional impact on neurode-
generative disease. ATP7A plays a role in Cu transport and
maintenance of Cu homeostasis that is critical for proper neu-
rological function such as axonal outgrowth, synapse integrity,
and neuronal activation37. Homology modeling of ATP7A, which
consists of transmembrane regions (MA, MB, and M1-M6) and
cytosolic N-, P-, and A-domain, indicates that M1311 residue is
located next to the ATP binding site in core cytosolic P-domain,
which induces conformational changes during copper transport
process. The M1311 residue has hydrophobic interaction with
residues on P- and A-domain, and also has hydrogen interaction
with residues on P-domain. In homology model with M1311V
mutation, the mutated residue seems to break hydrophobic
contacts or hydrogen bond interaction depending on the orien-
tation of valine and surrounding residues (Supplementary
Fig. 11). From the molecular modeling study, we hypothesized
that ATP7A M1311V mutation disturbs internal interactions
between residues on A- or P-domain, and thereby negatively
affects the function of Cu binding and its transporting of ATP7A
proteins46–49, which may cause neurodegenerative mechanism in
the patient. Alternatively, our results showed that the gene cor-
rection of ATP7A M1311V dramatically improves the neuronal
morphology and function, which strongly supports the
hypothesis.
To date, many researchers have worked to reveal interactions
between genetic variants and disease phenotypes. Recently,
Fig. 3 Gene correction of the ATP7A M1311V mutation results in improvement of pathophysiology. a Time table showing differentiation protocol used
for NPC from patient-derive iPS and MN from NPC. DMSB, Dorsomorphin and SB431542; EB, Embryoid body; RA, Retinoic acid; SAG, Smoothened Agonist;
NTFs, Neurotrophic factors; EP, Electrophysiology. b Immunostaining with the anti-Nestin antibody in NPCs and anti-Tuj1 antibody after 3 weeks
differentiation. Scale bars, 50 µm. c The Nestin-positive cells normalized to that of the 4′, 6-diamidino-2-phenylindole (DAPI)-positive area. n= 9. d The
Isl1/2-positive cells normalized to that of the 4′, 6-diamidino-2-phenylindole (DAPI)-positive area. n= 14. e Immunostaining with the anti-isl1/2 antibody
and anti-MAP2 antibody after 3 weeks differentiation. Scale bars, 50 µm. f The microtubule associated protein 2 (MAP2)-positive area normalized to that
of the 4′, 6-diamidino-2-phenylindole (DAPI)-positive area. n= 13. g Immunostaining with the anti-MAP2 antibody (red). DAPI (blue) was used for nuclear
staining. Scale bars, 50 µm. h LDH activity in motor neurons (MNs). n= 24 (Control-MN), n= 26 (ATP7A-M1311V-MN), and n= 20 (ATP7A-Cor1-MN).
i, Quantification of the reactive oxygen species (ROS) level. n= 11 (Control-MN), n= 22 (ATP7A-M1311V-MN), and n= 14 (ATP7A-Cor1-MN). j,
Quantification of the mitochondrial membrane potential using tetramethylrhodamine ethyl ester (TMRE) assay. n= 16 (Control-MN), n= 22 (ATP7A-
M1311V-MN), and n= 12 (ATP7A-Cor1-MN). Data are presented as mean ± s.e.m,; unpaired two-tailed t test with Welch’s correction. Source data used for
the graphs in (c, d, f) and (h–j) can be found in Supplementary Data 1.
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genome-wide quantification analyses have shown that rare
mutations are found in normal tissue, whereas risk variants from
neurodevelopmental disorder patients are common genetic var-
iants, implying that non-rare genetic variants may cause genetic
disease in some patients50–55. In this study, we showed that
correction of the ATP7A M1311V mutation can rescue the
function of MNs derived from cells of one ALS patient of Ash-
kenazi Jewish descent. However, the ATP7A M1311V allele fre-
quency is not rare in Ashkenazi Jews (0.01991), whereas it is rare
in other ethnic populations (0–0.0003) such as European, Asian,
Latino, and African. Because ALS is known to be a multifactorial
disease and over 100 genes are intricately involved29,56–58, the
ATP7A gene may act as one crucial component in an ALS-related
network and the ALS disease may be caused by a combination of
other disease factors such as genetic defects of other variants in a
patient’ genome, altered transcripts, and epigenetic and envir-
onmental factors together with ATP7A M1311V59–62. In our
results of trio-based WGS, the patient had many genetic variants
in addition to the variants in ATP7A. Although we prioritized the
ATP7A M1311V mutation as a strong candidate for ALS
pathogenesis because of its higher pathogenic score and the X-
linked recessive mutation, we could not exclude other variants
completely, which might be a further study. From one deep
individual study, we suggest that a non-rare genetic variant in an
ALS patient has a potential to be responsible for the disease.
Furthermore, in the case of this ALS patient, ATP7A M1311V
might be a potential therapeutic target, elucidated by our perso-
nalized medicine strategy.
Methods
Human samples. This study includes one trio family (affected patient and unaf-
fected parents) of Ashkenazi Jewish descent. Tissue sample was obtained by Gary
Bassell and Chadwick Hales and the healthy donor sample was kindly provided by
Zachary T. McEachin at Emory University. The Institutional Review Board (IRB)
of Severance Hospital approved this study (IRB approval number: 4-2012-0028).
Whole genome sequencing (WGS). Steps in the WGS analysis for the unaffected
parents and the affected patient, such as alignment, variant calling, annotation, and
candidate variant selection, are summarized below and detailed in Supplementary
Fig. 1. Genomic DNA was extracted from blood. A library of DNA fragments was
constructed using a TruSeq PCR-free Library Preparation Kit (Illumina). Paired-
end sequencing of the library was performed using rapid run v2.0 (Illumina)
chemistry on a GiSeq 2500 (Illumina) sequencer according to the manufacturer’s
recommended protocol. The genome was sequenced to a mean read depth of <30X.
Fig. 4 Action potential and current traces of voltage-gated sodium and potassium channels in gene-corrected MNs. a Morphology of neural precursor
cells (NPCs) after differentiation for 8 weeks for electrophysiology experiments. BF, bright field. Scale bars, 20 µm. b Representative traces of different
types of action potentials: none, single, adaptive, repetitive. Repetitive firing was defined as action potentials that lasted for the duration of the current
injection (1 s), whereas adaptive firing was defined as multiple action potentials that ceased before the end of the current injection. Comparisons between
ATP7A-M1311V MNs and the other groups of cells were performed using data from recordings of firing cells. c Proportion of cells firing in each category as
a measure of functional maturation. n= 23 (Control-MN), n= 25 (ATP7A-M1311V-MN), and n= 25 (ATP7A-Cor1-MN). The differences between groups
were assessed using Fisher’s exact test with Bonferroni correction. d Sodium currents of Control-MN (n= 23), ATP7A-M1311V-MN (n= 25), and ATP7A-
Cor1-MN (n= 30). Every data point was compared with the peak of the sodium current for ATP7A-M1311V-MN. e Potassium currents of Control-MN (n=
23), ATP7A-M1311V-MN (n= 25), and ATP7A-Cor1-MN (n= 30). Every data point was compared with the peak of the potassium current for ATP7A-
M1311V. The error bars indicate ± s.e.m.; statistical analysis was performed using two tailed t-test. *p < 0.05, **p < 0.01. Source data used for the graphs in
(c–e) can be found in Supplementary Data 2.
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Raw FASTQ format sequences were aligned to the hg19 reference genome using
BWA-MEM and generated to BAM file format. PCR duplicates were removed,
known alleles were marked (dbsnp version 138, b37), and defined intervals were
targeted for local realignment, after which indels were realigned with default
options. We then additionally filtered for aligned files with MQRankSum (Z-score
from Wilcoxon rank sum test of Alt vs. Ref read mapping qualities) <−12.5,
ReadPosRankSum (Z-score from Wilcoxon rank sum test of Alt vs. Ref read
position bia) <−8.0, QD (Quality of Depth) < 2.0, FS (Phred- scaled p-value using
Fisher’s exact test to detect strand bias) > 60.0 or FS > 200, and MQ (RMS Mapping
Quality) < 40.0. After filtering, the following numbers of single nucleotide variants
(SNVs) remained: 4,667,802 for the affected patient, 4,641,608 for the unaffected
father, and 4,643,959 for the unaffected mother.
Mutations were called from the alignment files using GATK haplotype caller
following GATK Best Practices recommendations. The VCF files produced by the
pipeline use reference allele based on the positive strand of hg19 in the REF field,
and variants were shown in the ALT field.
Relatedness was tested for the trio by comparing single nucleotide
polymorphism (SNP) concordance between the patient and parents using vcftool.
We carried out variant analysis based on pedigree information. X-linked variants
were selected if they were present in the patient and mother, but not in the father.
De novo variants were chosen if the variants were only present in the patient and
not in either parent or by using the TrioDeNovo program. After this analysis, 3517
X-linked variants, 10,754 autosomal recessive variants, and 19,959 de novo variants
remained. We annotated each variant type using snpEff and panels of normal
populations such as the 1000 Genome Project (1KGP) and the Exome Aggregation
Consortium (ExAC).
WGS data analysis. We selected functionally important variants with high or
moderate impacts in SO. For variants in coding regions, we selected those with
functional importantance, such as missense, nonsense, and splicing variants. We
next selected rare variants by excluding alleles with a global minor allele frequency
> 5% in dbSNPv135, a global minor allele frequency in 1KGP > 2%, a minor allele
frequency in ExAC > 5%, and a minor allele frequency in the Ashkenazi Jewish
population > 5% in gnomAD r2.0.2.
We then followed the guidelines of the American College of Medical Genetics to
prioritize variants. Those variants passing the pathogenicity predictions were
annotated using SIFT and PolyPhen-2 scores. We used two algorithms to predict
the impact of protein sequence variants for missense variants. SIFT is based on
sequence homology and the physical properties of amino acids, and PolyPhen-2 is
based on eight sequence and three structure predictive features. Possibly damaging
SNVs (PDSs) were extracted from these datasets. We then reviewed existing
literature on neurodegenerative diseases, protein structures, and pathways. These
steps yielded information on a variant’s functional importance, predicted the
resulting damage to protein function, and indicated biologically relevant pathways.
In addition to prioritization, we manually checked for alignment quality with
Integrated Genomic Viewer (IGV, https://www.broadinstitute.org/software/igv)
and cBioPortal (http://www.cbioportal.org/mutation_mapper.jsp).
Network-based gene prioritization. To prioritize the selected genes with func-
tionally important variants, we performed a network-based gene prioritization
method that propagates functional scores via a network model. There are two
approaches for network propagation, which are direct neighbor and network dif-
fusion. The former can transmit the functional score only by direct links in the
network model. The representative algorithm is naïve Bayes63, in which the score
of a particular node label is the sum of the network edge weights of all of the
connected neighbors for the same label. The latter can diffuse the functional score
throughout the entire network, typically by Gaussian smoothing (GS)64. The GS
algorithm finds an optimal solution in which it achieves a minimal difference
between the initial and final scores of a labeled gene, and also between the label
score of a gene and each of its neighbors.
In our study, we first chose the STRING v10.565 database as the base network
model. STRING v10.5 includes direct (physical) interactions, as well as indirect
(functional) interactions such as co-expression, shared selective signals across
genomes, text-mining of the scientific literature, and transfer of interaction
knowledge between organisms based on gene orthology. Using high-confidence
(confidence score >0.7) links of STRING v10.5 and genes known to be linked with
amyotrophic lateral sclerosis (ALS) (Supplementary Table 3) collected from the
database29, we prioritized the ALS candidate genes by both network propagation
approaches, and selected ALS candidate genes with functionally important variants
(Supplementary Tables 4 and 5).
Induced neural stem cell (iNSC) direct reprogramming. Reprogramming into
iNSCs was performed using a previously described method45 with slight mod-
ifications. Briefly, Sendai reprogramming vectors (CytoTune-iPS 2.0 Sendai
Reprogramming Kit, Thermo Fisher Scientific) were transduced into 30,000
fibroblast cells according to the manufacturer’s instructions. The next day, the
culture medium was replaced with a neural reprogramming medium (RepM-
Neural: Advanced DMEM/F12 and Neurobasal medium were mixed at a ratio of
1:1 and supplemented with 0.05% AlbuMAX-I, 1× N2, 1× B27 minus vitamin A,
2 mM GlutaMAX, 0.11 mM β-mercaptoethanol, all from Thermo Fisher Scientific),
and cells were cultured for 18–21 days. During reprogramming, a chemical cocktail
including 0.2 mM NaB (Sigma), 3 μM CHIR99021 (Tocris), and 0.5 μM A83-01
(Tocris) was added to the medium before use. The resulting colonies were
manually picked and maintained in a RepM-Neural medium containing 3 μM
CHIR99021, 0.5 μM A83-01, and 10 ng ml−1 hLIF (Sigma).
RNA extraction and quantitative PCR were performed as previously described66
using a Power SYBR Green Kit (Applied Biosystems). The primer sequences were as
follows: 5′-TCTTTGCTTGGGAAATCCG-3′ (PAX6 forward), 5′-CTGCCCGTTCAA
CATCCTTAG-3′ (PAX6 reverse), 5′-TGGCTAAGAACATCGGAAGG-3′ (SeV
forward), 5′-GTTTTGCAACCAAGCACTCA-3′ (SeV reverse).
ATP7A homology model generation. Discovery studio 2018 software (Dassault
Systèmes BIOVIA, Discovery Studio Modeling Environment, Release 2018, San
Diego: Dassault Systèmes, 2018.) was used for our protein structure modeling
study. An ATP7A homology model was created using the 2.75 Å X-ray crystal
structure of P1B-ATPase (E2P state) from Legionella pneumophila (PDB ID 4BBJ)46.
The template structure (4BBJ) has transmembrane (TM) helices and cytosolic N-,
P-, and A-domains but excludes heavy metal binding domains. This structure was
obtained in copper-free E2P state after Cu was transported through the TM
domain. The ATPase_human sequence (Q04656) was aligned to the template,
and it showed an 18.7% sequence identity and 30.0% sequence similarity. Initi-
ally, 20 homology models were created and validated using the DOPE score and
Ramachandran plot. Validated structures were then selected for methionine
residue interaction analysis. Ten models for the ATP7A M1311V mutant were
then created, and the effects of the mutation on interactions between residues
were analyzed. Images were rendered using PyMOL software (www.pymol.org)
and Discovery Studio 2018 software.
Construction and evaluation of single guide RNAs (sgRNAs). All sgRNAs were
designed using Cas-Designer (http://www.rgenome.net/cas-designer/), and two
complementary oligos encoding each sgRNA were annealed and ligated with a
plasmid used for sgRNA expression, which had been linearized with BsaI
(New England Biolabs). Oligos were purchased from Macrogen Inc (South
Korea). A list of oligos used to generate sgRNAs is provided in Supplementary
Fig. 5.
Patient-derived fibroblasts were grown in Dulbecco’s Modified Eagle Medium
(DMEM, WELGENE) with 10% fetal bovine serum (FBS) (WELGENE), 0.2%
penicillin/streptomycin mix (Gibco), 1x MEM NEAA (Gibco), and 55 μM β-
mercaptoethanol (Sigma). 150,000 patient-derived fibroblasts were co-transfected
with 500 ng of Cas9-encoding plasmid and 500 ng of sgRNA-encoding plasmid
using a Neon™ Transfection System (Invitrogen) with the following parameters:
voltage, 1600; width, 20 ms; number, 1. Three days after transfection, the cells were
harvested, and genomic DNA was isolated using NucleoSpin Tissue (MACHEREY-
NAGEL & Co. KG) according to the manufacturer’s protocol. The genomic DNA
was amplified and analyzed by targeted deep sequencing.
Establishment of gene-corrected isogenic iPS cell lines. The iPS cell lines from
the patient and a healthy donor were established by Zachary T. McEachin using
CytoTune-iPS Sendai Reprogramming Kits. To produce the normal ATP7A
sequence, patient-derived iPS cells were transfected with plasmids encoding Cas9
and sgRNA targeting the ATP7A M1311V mutation with the appropriate single-
stranded oligodeoxynucleotides (ssODNs) as a donor DNA. On day 3, transfected
iPS cells were detached with ReLeSR™ (Stem Cell Technologies) and split for clump
passage accompanied by serial dilution. When colonies containing round-shaped
iPS cells were formed at around 7–14 days, they were detached using ReLeSR™. A
small proportion of cells from colonies was harvested for targeted deep sequencing,
and the leftover cells were transferred for further expansion. To prepare genomic
DNA, cell pellets were resuspended in 50–100 μl of Proteinase K extraction buffer
[40 mM Tris-HCl (pH 8.0) (Sigma), 1% Tween-20 (Sigma), 0.2 mM EDTA
(Sigma), 10 mg of proteinase K, 0.2% nonidet P-40 (VWR Life Science)], incubated
at 60 °C for 15 min, and heated to 98 °C for 5 min, and the genomic DNA was
amplified and analyzed by targeted deep sequencing. Colonies with high fre-
quencies of homology-directed repair (HDR) were picked for repeated clump
passage accompanied by serial dilution and genotyping. As the HDR frequency was
increased through this process, colonies containing the normal ATP7A sequence
were established. Karyotyping was conducted at Gendix, Inc (Seoul, South Korea).
Genotyping. Hundred nanogram of genomic DNA or 2–3 μL of Proteinase K
extraction solution was amplified by three-round PCR using SUN-PCR blend
(SUN GENETICS). The following programs were used for the first round PCR:
3 min at 95 °C; 25 cycles of 30 s at 95 °C, 30 s at 60 °C, and 60 s at 72 °C; and,
finally, 3 min at 72 °C. 1 µL of the first round PCR product was used for the second
round PCR. The following programs were used: 3 min at 95 °C; 25 cycles of 30 s at
95 °C, 30 s at 60 °C, and 20 s at 72 °C; and, finally, 3 min at 72 °C. 1 µL of the
second round PCR product was used for the third round PCR. The following
programs were used: 3 min at 95 °C; 30 cycles of 30 s at 95 °C, 30 s at 62 °C, and
20 s at 72 °C; and, finally, 3 min at 72 °C. The amplified genomic DNA regions
containing a Cas9-targeted site were purified using Expin™ PCR SV mini (GeneAll)
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according to the manufacturer’s protocol. The PCR amplicons were sequenced
using a MiniSeq Sequencing System (Illumina), and the results were analyzed using
Cas-Analyzer (http://www.rgenome.net/cas-analyzer/). A list of primers for PCR is
provided in Supplementary Fig. 6.
Cell culture and neural differentiation of iPS cells. The iPS cells were cultured in
mTeSR™1 (Stem Cell Technologies) medium on hESC-qualified Matrigel (Corn-
ing)-coated culture dishes. To induce embryoid body (EB)-mediated neural rosette
formation, iPS cells were harvested using 2 mgml−1 collagenase IV (Gibco) and
EBs were suspension cultured for 4 days with 5 μM SB431542 (SB) (Tocris)
and 5 μM Dorsomorphin (DM) (Tocris) in TeSR™-E6 (Stem Cell Technologies)
medium. On day 5, EBs were attached to Matrigel-coated culture dishes containing
DMEM/F12 (Gibco) supplemented with 1× N2 (Gibco), 20 ng ml−1 basic fibroblast
growth factor (bFGF) (R&D system), and insulin (Sigma) and grown for an
additional 5 days. Neural rosettes that appeared in the center of EBs were isolated
using a pulled glass pipette and cultured on Matrigel-coated culture dishes in
neural progenitor cell (NPC) medium (DMEM/F12 medium supplemented with 1×
N2, 1× B27 (Gibco), 20 ng ml−1 bFGF (R&D system) and 20 ng ml−1 epidermal
growth factor (EGF) (Peprotech)). This medium was replaced every 2 days for the
following week. PSA-NCAM positive NPCs were used to motor neuron differ-
entiation. NPCs were seeded at low density on Matrigel-coated culture dishes in
differentiation medium (NPC medium deprived of bFGF and EGF) with 1 μM
retinoic acid (RA) (Sigma) and 0.5 μM Smoothened Agonist (SAG) (Millipore). On
day 7 of differentiation, RA and SAG were withdrawn and the medium was
changed to differentiation medium plus 0.1% fetal bovine serum (FBS) (Hyclone),
200 μM ascorbic acid (Sigma), 10 ng ml−1 each of brain derived neurotrophic
factor (BDNF), glial-derived neurotrophic factor (GDNF), and ciliary neurotrophic
factor (CNTF) (Peprotech). For further maturation, differentiated cells were
maintained in differentiation medium with 0.1% FBS. All cell lines were differ-
entiated in parallel and compared at the same time.
Isolation of PSA-NCAM positive cells. Neural rosette cells were expanded to a
confluence of 80–90% and treated with 10 μM Y27632 (Stem Cell Technologies) for
1 h to prevent cell death. After dissociation with Accutase (Gibco), the cells were
pelleted, resuspended in a solution containing 0.5% bovine serum albumin (BSA)
(Gibco) in 1x phosphate buffered saline (PBS), and incubated on ice for 10 min.
Anti-PSA-NCAM Microbeads (Miltenyi Biotec) were added to the solution, which
was then incubated on ice for 15 min. Cells were washed in 1× PBS and loaded on a
LS column for magnetic separation. The column was washed with 1× PBS, causing
unlabeled cells to pass through, after which the plunger was pushed into the
column to flush out magnetically labeled cells.41
Sanger sequencing validation of the ATP7A sequence. The 5 mutation variants
(DTX1, NOTCH2, GFRA, GART, and ATP7A) were confirmed by Sanger
sequencing. The genomic DNA was extracted from the ALS-patient derived
fibroblasts and GM14867 using NucleoSpin Tissue (MACHEREY-NAGEL & Co.
KG) according to the manufacturer’s protocol, and 100 ng of the genomic
DNA were amplified using KOD -Multi & Epi- (TOYOBO) under the
following conditions: 2 min at 94 °C; 35 cycles of 10 s at 98 °C, 30 s at 60 °C, and
20 s at 68 °C; and, finally, 2 min at 68 °C. The primer sequences were as follows: 5′-
CCTGTGCTGAACCTCATGC-3′ (DTX1 forward), 5′-TGAGCGGGTAGGCGA
GGT-3′ (DTX1 reverse), 5′-TGCTGAGGTCCTTGGAGAGT-3′ (NOTCH2 for-
ward), 5′-ACACCCACTACCTCCTGTG-3′ (NOTCH2 reverse), 5′-GTTCAGCA
GAGGGAATCTGG-3′ (GFRA2 forward), 5′-ACCCTATAGCCTGCAAAGCA-3′
(GFRA2 reverse), 5′-TCTCCCTTCTCAGGATCGAA-3′ (GART forward), 5′-
TTCTGGGATGGGTGTTCACT-3′ (GART reverse), 5′-TGATAGATGCTGCCA
GATGC-3′ (ATP7A forward), and 5′-GCTGGGTTGAGAAAGTCAGG-3′
(ATP7A reverse). The amplified genomic DNA was purified using Expin™ PCR SV
mini (GeneAll) or Expin™ Gel SV mini (GeneAll) according to the manufacturer’s
protocol. Sanger sequencing were performed at Macrogen Inc.
The ATP7A sequence was validated by Sanger sequencing of genomic DNA that
was extracted from iPS cells, NPCs, and MNs using a Genomic DNA Extraction Kit
(Bioneer) and amplified by PCR using the following conditions: 5min at 95 °C;
35 cycles of 30 s at 95 °C, 30 s at 58 °C, and 60 s at 72 °C; and, finally, 10min at 72 °C.
The primer sequences were as follows: 5′-ATTGCTCAGTTATGTTTCACGTACTC-3′
(ATP7A forward) and 5′-TCTTAATGGCTGATAGCATGGAACT-3′ (ATP7A
reverse). Sanger sequencing experiments were performed at Macrogen Inc.
Electrophysiology. Whole-cell patch-clamp recordings were used to investigate
the functionality of ALS neurons. The ALS neurons were differentiated for 8 weeks
and transferred to a recording chamber, and perfused with aerated (95% O2/5%
CO2 mixed gas) artificial cerebrospinal fluid bath solution containing 124-mM
NaCl, 3-mM KCl, 1.3-mMMgSO4, 1.25-mM NaH2PO4, 26-mM NaHCO3, 2.4-mM
CaCl2-2H2O, and 10-mM glucose at 32 °C. Patch pipettes (open pipette resistance,
2–5MΩ) were filled with an internal solution consisting of 140-mM K+ -gluco-
nate, 10-mM NaCl, 1-mM CaCl2, 10-mM HEPES, 0.2-mM EGTA, 5-mM Mg-ATP
and 0.5-mM Na-GTP. For confirmation test, 0.5-µM tetrodotoxin and 5-mM
tetraethylammonium were used (Supplementary Fig. 9). ALS neurons were
visualized with Olympus upright BX51WI microscope with 60× immersion lens.
Patch electrodes were pulled on Sutter P-97 horizontal puller (Sutter Instrument
Company) from borosilicate glass capillaries (World Precision Instruments, Sar-
asota, FL). Recorded signals were amplified using MultiClamp 700B amplifier
(Axon Instruments, Union City, CA), and data acquisition was performed using
Digitizer 1550B and pClamp10 software (Axon Instruments). Intrinsic membrane
properties were investigated using voltage clamp mode, and firing properties were
investigated using current-clamp mode. To measure sodium and potassium cur-
rents, cells were stimulated with 100-ms voltage steps of depolarizing current
starting from −60 mV to +20 mV (+10 mV per step). In current-clamp mode,
cells were subjected to a series of current injections to examine action potential
generation. Only cells with a series resistance that was less than 20MΩ, and a
resting membrane potential (RMP) that was more hyperpolarized than −20 mV
were included in data analysis.
LDH assay. To measure released LDH, MNs were differentiated from NPCs as
described above for 3 weeks. The cell culture medium was transferred to 1.5-ml
microcentrifuge tubes, and centrifuged at 2000 rpm for 3 min to remove cell debris,
after which the supernatant was transferred to new 1.5-ml microcentrifuge tubes.
Released LDH was measured using a commercially available LDH assay kit
(Abcam). Sample absorbance was measured at OD 450 nm, and LDH concentra-
tion was calculated according to the manufacturer’s instructions.
Treatment of cells with copper and glutamate. iNSCs were treated with
CuSO4∙5H2O (Sigma) to examine the effects of Cu on ROS levels and LOX activity.
Cells were seeded, incubated for 24 h, and then exposed to Cu at various con-
centrations. After 4 h, cells were washed with Dulbecco’s PBS (DPBS), and ROS
and LOX assays were performed. MNs were treated with 1-mM glutamate (Sigma)
to test glutamate vulnerability and effects of glutamate on ROS levels. After 1 h,
cells were washed and MTT and ROS assays were performed, or cells were
immunostained with antibodies recognizing cleaved caspase-3.
MTT assay. The 3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide
(MTT) assay was used to measure glutamate-induced cell toxicity. Cells were
seeded in 96-well plates, incubated for 24 h, and then treated with 1-mM glu-
tamate for 1 h. Cells were then washed with DPBS (Gibco), and MTT assay was
performed. The 0.5 mg ml−1 MTT solution (Sigma) was added to each well, and
plates were incubated at 37 °C for 4 h. The reaction was stopped by removing
MTT solution and adding dimethyl sulfoxide to dissolve the formazan crystals.
VersaMax ELISA Microplate Reader (Molecular Device) was used to read the
absorbance at 560 nm.
Cell viability assay. To quantify cell viability, live and dead cells were stained
using a LIVE/DEAD Cell Viability/Cytotoxicity Kit (Thermo Fisher Scientific) in
accordance with the manufacturer’s protocol. Briefly, calcein AM was used to stain
live cells and ethidium homodimer-1 was used to stain dead cells. Cells were
exposed a mixture of the two dyes and incubated at room temperature for 15 min.
Cells were counted using live images randomly captured by fluorescence micro-
scopy, and analyzed using Image J software.
Immunocytochemistry. MNs and iNSCs were fixed with 4% paraformaldehyde at
room temperature for 10 min and washed with 0.3% Tween 20 in PBS. Cells were
blocked with 10% normal donkey serum, 0.3% Triton-X in PBS at room tem-
perature for 1 h, and incubated with primary antibodies at 4 °C overnight. Cells
were then washed with 0.3% Tween 20 in PBS, and incubated with secondary
antibodies (Jackson Immunoresearch) at room temperature for 30 min. Images
were acquired using an LSM-700 confocal microscope (Carl Zeiss). Primary anti-
bodies recognizing the indicated proteins were obtained as follows: MAP2
(Abcam), cleaved caspase-3 (Cell Signaling Technology), Tuj1 (Abcam), Ki67
(ZYMED, Abcam), PAX6 (DSHB), Sox2 (R&D Systems), Nestin (Santa Cruz),
PLZF and N-CAD (Millipore); 4′, 6-diamidino-2-phenylindole (DAPI) (Santa
Cruz Biotechnology) and Hoechst (Millipore) were used for nuclear staining. For
further analysis of neuronal morphology, Image J was used to study cells stained
with anti-MAP2 antibodies and DAPI.
Reactive oxygen species (ROS) measurement. ROS levels were measured in
live cells using 2′,7′-dichlorofluorescin diacetate (DCFDA) (Sigma). The iNSCs
and NPCs were seeded a day before the assay was performed, while MNs were
differentiated from NPCs for 3 weeks beforehand. Cells were exposed to
1-μM DCFDA for 30 min at 37 °C. Fluorescence indicative of ROS was measured
with at Ex/Em= 485/535 nm, and the fluorescence level was normalized
O.D. unit.
Lysyl oxidase (LOX) assay. The iNSCs and NPCs were seeded a day before the
assay was performed, while MNs were differentiated from NPCs 3 weeks before-
hand. Cell samples were harvested and lysed with 200-μl lysis buffer. LOX activity
was determined using a commercially available LOX assay kit (Abcam) according
to the manufacturer’s protocol. Fluorescence was detected at Ex/Em= 540/590 nm
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and normalized to the protein concentration measured using BCA kit (R&D
Systems).
Mitochondrial membrane potential assay. MNs were differentiated from NPCs
for 3 weeks beforehand. A day prior to assay, MNs were re-seeded in 96-well plates
at a density of 2 × 104. Mitochondrial membrane potential was determined by
cytofluorimetric analysis after staining with tetramethylrhodamine ethyl ester
(TMRE) (Abcam) at concentration of 1 μM for 30 min at 37 °C. Fluorescence
indicative of TMRE was measured with at Ex/Em= 510/580 nm.
Statistical analysis and Reproducibility. Values are expressed as means ± s.e.m.,
and the differences between groups were assessed using unpaired two-tailed t test
with Welch’s correction, and Fisher’s exact test and proportion test with Bonfer-
roni correction. Multiple t test with correction for multiple comparisons using the
Holm-Sidak method and Bonferroni-Dunn method was used for multiple com-
parisons. P values less than 0.05 were considered significant. Statistical analysis was
performed with GraphPad Prism7 (San Diego, CA, USA). In cases of using NPCs
and MNs, all experiments were biologically replicated across 2 independent neural
differentiations from iPSCs. That is, from one corrected iPSC line (ATP7A-Cor1),
we repeatedly differentiated it to neural progenitor cells (ATP7A-Cor1-NPCs) and
further motor neurons (ATP7A-Cor1-MNs). In case of using iNSCs, all experi-
ments were reproduced at least 4 times. All attempts for replication were successful.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
Targeted deep sequencing data have been deposited in the NCBI Sequence Read Archive
database (SRA; https://www.ncbi.nlm.nih.gov/sra) under accession number
PRJNA531568.
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